Literature DB >> 30285916

Effect of an Electronic Alert on Targeted HIV Testing Among High-Risk Populations.

Rulin C Hechter1, Zoe Bider-Canfield2, William Towner3.   

Abstract

CONTEXT: Screening for HIV infection in medical settings remains suboptimal.
OBJECTIVE: To examine the real-world effectiveness of an electronic clinician alert on the same-day HIV testing rate and early diagnosis in high-risk populations.
DESIGN: We identified Kaiser Permanente Southern California Health Plan members aged 14 years or older who received tests for sexually transmitted infections. MAIN OUTCOME MEASURES: Encounter-based same-day HIV testing rate, positive test result rate, and CD4+ cell count and HIV viral load at diagnosis.
RESULTS: We identified 1,800,948 patients who made 2,326,701 health care encounters eligible for HIV testing before implementation (January 1, 2008 - June 30, 2012) and 1,362,479 eligible encounters after implementation (January 1, 2013 - June 30, 2015). The same-day HIV testing rate increased from 36.7% to 44.1% (standardized mean difference = 0.15, significant difference). The alert was associated with a moderate difference and statistically significant increase in the HIV testing rate (adjusted odds ratio = 1.17, 95% confidence interval = 1.16-1.18). The positive test result rate increased from 0.02% to 0.04% (p < 0.001). During the postimplementation period, fewer HIV-infected patients had a CD4+ cell count below 200 and/or an HIV viral load of 10,000 copies/mL or higher at diagnosis.
CONCLUSION: Implementation of a targeted electronic alert embedded in the electronic medical record improved same-day HIV screening rate and positive test result rates among patients receiving tests for sexually transmitted infections in a large health organization. This intervention has potential for facilitating frequent screening and early identification of HIV infection in high-risk populations.

Entities:  

Mesh:

Year:  2018        PMID: 30285916      PMCID: PMC6172036          DOI: 10.7812/TPP/18-015

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  17 in total

1.  Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.

Authors: 
Journal:  Arch Intern Med       Date:  2011-09-26

2.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

3.  Monitoring HIV testing at visits to emergency departments in the United States: very-low rate of HIV testing.

Authors:  Jonathan B Hoover; Guoyu Tao; James D Heffelfinger
Journal:  J Acquir Immune Defic Syndr       Date:  2013-01-01       Impact factor: 3.731

4.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

5.  The economic burden of late entry into medical care for patients with HIV infection.

Authors:  John A Fleishman; Baligh R Yehia; Richard D Moore; Kelly A Gebo
Journal:  Med Care       Date:  2010-12       Impact factor: 2.983

6.  CD4 cell count criteria to determine when to initiate antiretroviral therapy in human immunodeficiency virus-infected children.

Authors:  Jurai Wongsawat; Thanyawee Puthanakit; Suparat Kanjanavanit; Rawiwan Hansudewechakul; Chaiwat Ngampiyaskul; Stephen J Kerr; Sasiwimol Ubolyam; Tulathip Suwanlerk; Pope Kosalaraksa; Wicharn Luesomboon; Nicole Ngo-Giang-Huong; Mom Chandara; Vonthanak Saphonn; Kiat Ruxrungtham; Jintanat Ananworanich
Journal:  Pediatr Infect Dis J       Date:  2010-10       Impact factor: 2.129

7.  HIV Testing Among Men at Risk for Acquiring HIV Infection Before and After the 2006 CDC Recommendations.

Authors:  Candice K Kwan; Charles E Rose; John T Brooks; Gary Marks; Catlainn Sionean
Journal:  Public Health Rep       Date:  2016 Mar-Apr       Impact factor: 2.792

8.  Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.

Authors:  Corinna Koebnick; Annette M Langer-Gould; Michael K Gould; Chun R Chao; Rajan L Iyer; Ning Smith; Wansu Chen; Steven J Jacobsen
Journal:  Perm J       Date:  2012

9.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies.

Authors:  Peter C Austin
Journal:  Multivariate Behav Res       Date:  2011-06-08       Impact factor: 5.923

10.  Editorial commentary: immunodeficiency at start of antiretroviral therapy: the persistent problem of late presentation to care.

Authors:  Nathan Ford; Edward J Mills; Matthias Egger
Journal:  Clin Infect Dis       Date:  2014-12-16       Impact factor: 9.079

View more
  1 in total

Review 1.  Get2PrEP: An Electronic Medical Record Laboratory Comment Increased Safe Sex Counseling But Not Preexposure Prophylaxis Services at a Large Urban Academic Medical Center in Northern Manhattan.

Authors:  Rebecca Spicehandler; Jason Zucker; Caitlin Yumori; Matthew Adan; Caroline Carnevale; Deborah Theodore; Delivette Castor; Kathrine Meyers; Susan Whittier; Michael T Yin; Alwyn Cohall; Susan Olender; Peter Gordon; Magdalena E Sobieszczyk
Journal:  Sex Transm Dis       Date:  2022-07-29       Impact factor: 3.868

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.